Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia
about
Treating Negative Symptoms in Schizophrenia: an UpdatenAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation.Improving Current Treatments for Schizophrenia.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled TrialsPharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia.The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.Cognitive Control, the Anterior Cingulate, and Nicotinic Receptors: A Case of Heterozygote Advantage.Impaired visual, working, and verbal memory in first-episode, drug-naive patients with major depressive disorder in a Chinese population.Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q26744805-EE6AFA00-09F5-44AF-9998-C997A254F73DQ30362464-D26687F7-F16C-4A2C-AFE0-7FBCBA6FD2D1Q36243977-4D85889D-3DC0-4571-971B-4715764947F7Q38639637-4E1600FE-979D-4B40-8423-BC2490F1F949Q38699013-FA102396-A264-488C-A5FA-7A2C08B4EEA5Q38828405-948D894E-1BD4-446A-8D8C-3B9F5CA46761Q38955513-BC0046B9-9248-4178-B653-A9FC5A0542ACQ39233330-817A0A74-653C-4FAE-8381-3218F0DACCCCQ41687338-9E27C882-0FE3-4F0E-81C6-8D06F72A9598Q42367850-7296A719-9E8B-4FB8-8671-486169ACCAC0Q47127039-25976F12-27D0-48C4-A145-D2E8A1250B2CQ47701023-C4849B0E-B62F-4645-B096-74EC68D73CDAQ48268464-B7C18772-79AE-4710-BB14-59B114AEB9B3Q52570051-0F441F1C-D7A8-4966-80F3-C50AD8D69800Q54975082-EC46B41C-2B43-4255-BE4F-4883848AD2DCQ58561523-58CAC29D-263E-4D22-BDF0-D3D21CCEF186
P2860
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@ast
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@en
type
label
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@ast
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@en
prefLabel
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@ast
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@en
P2093
P2860
P356
P1476
Phase 2 Trial of an Alpha-7 Ni ...... tive Symptoms of Schizophrenia
@en
P2093
Anthony C Segreti
Chris Dvergsten
David A Hosford
David Walling
Geoffrey C Dunbar
Jessica S Beaver
John E Jett
Richard S E Keefe
Stephen R Marder
P2860
P304
P356
10.1093/SCHBUL/SBV072
P407
P577
2015-06-12T00:00:00Z